Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hui Xu
Observed name:
H M Xu
Institutions:
Hubei University of Medicine,
Xiangya Hospital Central South University,
Xiang Yang No.1 People's Hospital
Observed institutions:
Hubei University of Medicine,
Peking University First Hospital,
Xiangya Hospital Central South University,
Xiang Yang No.1 People's Hospital
ORCID:
0009-0000-4667-4017
Observed ORCID:
0009-0000-4667-4017
OpenAlex ID:
A5081451260
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2023
·
Wei Zhou
, Peng Fang
, et al.
·
Molecular Cancer Therapeutics
·
50
PDF
Abstract 5733: Design and synthesis of the novel camptothecin analog MF-6 for application into site-specific antibody-drug conjugate
2025
·
Xiaowei Cen
, Hui Xu
, et al.
·
Cancer Research
·
1
Is Roxadustat Responsible for the Jaundice of a Dialysis Patient with β-Thalassemia? A Case Report
2025
·
Hong-Shan Zhou
, Han-Wei Huang
, et al.
·
Springer eBooks
·
1
PDF
Supplementary Fig.S9 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S15 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S14 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S5 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S7 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S6 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S9 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S16 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S7 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S11 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S2 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S13 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S2 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S12 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Fig.S5 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Supplementary Table S10 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
2025
·
Wei Zhou
, Peng Fang
, et al.
Show more works
View as search
Works count:
122
Citation count:
52
H-index:
1
I10-index:
1
Year
Topic
Type